Key regions: United Kingdom, Brazil, Europe, France, Canada
Anti-Fibrinolytic Drugs are a class of medication that helps to prevent the breakdown of blood clots. The ASEAN region has witnessed a significant increase in the demand for these drugs over the past few years.
Customer preferences: The rising prevalence of cardiovascular diseases, trauma, and surgical procedures has led to an increase in the demand for Anti-Fibrinolytic Drugs in ASEAN. Patients with bleeding disorders also require these drugs to control bleeding. Moreover, the affordability and accessibility of these drugs have also made them a popular choice among the population.
Trends in the market: Indonesia and Vietnam are witnessing a surge in the demand for Anti-Fibrinolytic Drugs due to the high prevalence of cardiovascular diseases in these countries. In Malaysia and Singapore, the demand for these drugs is primarily driven by the increasing number of surgical procedures. The Philippines and Thailand are also witnessing a rise in the demand for these drugs due to the growing prevalence of trauma cases.
Local special circumstances: In Indonesia, the government has launched several initiatives to increase awareness about cardiovascular diseases and promote the use of Anti-Fibrinolytic Drugs. In addition, the government has also made efforts to improve the affordability and accessibility of these drugs. In Vietnam, the government has implemented several policies to encourage the production and consumption of locally manufactured drugs, which has led to an increase in the availability of Anti-Fibrinolytic Drugs.
Underlying macroeconomic factors: The ASEAN region is witnessing a steady economic growth, which has led to an increase in the disposable income of the population. This, in turn, has led to an increase in the demand for healthcare services, including Anti-Fibrinolytic Drugs. Moreover, the increasing healthcare expenditure by the governments in the region has also contributed to the growth of the Anti-Fibrinolytic Drugs market in ASEAN.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
